Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-052-4
CAS number: 102-77-2
The carcinogenic potential of the test substance MBS was evaluated in a chronic feeding study with Sprague-Dawley rats (Monsanto Co. 1982). The incidence of tumour-bearing animals and the pattern of tumour multiplicity did not suggest any non-specific carcinogenic effect. The incidence of common tumour types was not enhanced by treatment and there was no evidence of any site-specific carcinogenicity in treated animals. Based on the finding of this study a NOAEL of 400 mg/kg bw and day is suggested.
No classification is required according to the classification criteria
67/548/EWG and regulation no. 1272/2008 (GHS).
The carcinogenic potential of MBS was evaluated in a chronic feeding
study with Sprague-Dawley rats (Monsanto Co. 1982). Male and female rats
(main experiment 50 per dose and sex, satellite group 10 per dose and
sex) were feed with the test substance MBS for 113 weeks (satellite
group 54 weeks). The animals were treated with 0, 5, 50 or 400 mg/kg bw
and day. Clinical changes seen in this study was generally typical of
that seen in the ageing CD rat. Treatment with the test substance MBS
did not appear to affect the incidence or severity of the observed
changes. An increase of the mortality rate was noted in males of the mid
and high dose group between week 58 and 85. Later in the study this
increase declined. In treated females (mid and high dose) a lower
mortality rat was seen compared to control in the latter part of the
study. The body weight gain was reduced in males and females of the high
dose group throughout the study. The reduced weight gain was associated
with slight reductions in food consumption. In haematology no
biologically relevant changes in haematological parameters were noted.
In clinical biochemistry and urine analysis some changes were noted, but
was considered as not biologically relevant (for more details see
endpoint repeated dose toxicity).
Gross pathology examinations revealed palpable subcutaneous masses
identified in a proportion of the animals in all groups in the course of
the study. The masses were of the type commonly seen in the CD rat and
were most frequently seen in the axillae and mammary glands. The time to
first mass was not affected by treatment. Males of the mid and high dose
groups showed a statistically significant increase in palpable masses,
whereas the corresponding female groups showed a reduced incidence. The
microscopic pathology data did not indicate this to be a carcinogenic
There was no apparent difference between animals of the highest dose
group (400 mg/kg bw and day) and the control animals in the incidence of
tumour-bearing animals or in the incidence of animals with tumours of
single or multiple organ sites. The authors concluded that the incidence
of common tumour types was not enhanced by treatment and there was no
evidence of any site-specific carcinogenicity.
Based on the finding of this study a NOAEL of 400 mg/kg bw and day is
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again